ID: ALA4641721

Max Phase: Preclinical

Molecular Formula: C22H26Cl2N6

Molecular Weight: 445.40

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1nn([C@H](C)c2ccc(Cl)cc2Cl)c2nc(N3CC(N4CCCCC4)C3)cnc12

Standard InChI:  InChI=1S/C22H26Cl2N6/c1-14-21-22(30(27-14)15(2)18-7-6-16(23)10-19(18)24)26-20(11-25-21)29-12-17(13-29)28-8-4-3-5-9-28/h6-7,10-11,15,17H,3-5,8-9,12-13H2,1-2H3/t15-/m1/s1

Standard InChI Key:  PZGLNMPUBXIDMH-OAHLLOKOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 445.40

Molecular Weight (Monoisotopic): 444.1596

AlogP: 4.73

#Rotatable Bonds: 4

Polar Surface Area: 50.08

Molecular Species: NEUTRAL

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.02

CX LogP: 4.68

CX LogD: 3.96

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.58

Np Likeness Score: -1.30

References

1. Robles O, Jackson JJ, Marshall L, Talay O, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Ketcham JM, McKinnell J, Meleza C, Reilly MK, Riegler E, Shunatona HP, Wadsworth A, Younai A, Brockstedt DG, Wustrow DJ, Zibinsky M..  (2020)  Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.,  63  (15): [PMID:32667798] [10.1021/acs.jmedchem.0c00988]

Source

Source(1):

• Scientific Literature